Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases

EP4634382A1Pending Publication Date: 2025-10-22UNIVERSITY OF STRASBOURG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023833070
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-16
Filing Date
2023-12-15
Publication Date
2025-10-22

Smart Images

  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000040_0001
    Figure IMGF000040_0001
  • Figure 00000052_0000
    Figure 00000052_0000
Patent Text Reader

Abstract

The invention provides RNA interfering agents targeting human Claudin-1 for use in the treatment and / or prevention of fibrotic diseases, including liver fibrosis, lung fibrosis and kidney fibrosis. Also provided are pharmaceutical compositions and kits comprising such RNA interfering agents and methods for administering such RNA interfering agents to patients suffering from fibrotic diseases.
Need to check novelty before this filing date? Find Prior Art